Correlation Between DiaMedica Therapeutics and Edgewise Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Edgewise Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Edgewise Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DiaMedica Therapeutics and Edgewise Therapeutics, you can compare the effects of market volatilities on DiaMedica Therapeutics and Edgewise Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Edgewise Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Edgewise Therapeutics.

Diversification Opportunities for DiaMedica Therapeutics and Edgewise Therapeutics

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between DiaMedica and Edgewise is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Edgewise Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Edgewise Therapeutics and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Edgewise Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Edgewise Therapeutics has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Edgewise Therapeutics go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Edgewise Therapeutics

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to under-perform the Edgewise Therapeutics. In addition to that, DiaMedica Therapeutics is 1.09 times more volatile than Edgewise Therapeutics. It trades about -0.12 of its total potential returns per unit of risk. Edgewise Therapeutics is currently generating about -0.05 per unit of volatility. If you would invest  2,706  in Edgewise Therapeutics on December 30, 2024 and sell it today you would lose (379.00) from holding Edgewise Therapeutics or give up 14.01% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

DiaMedica Therapeutics  vs.  Edgewise Therapeutics

 Performance 
       Timeline  
DiaMedica Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Edgewise Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Edgewise Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

DiaMedica Therapeutics and Edgewise Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DiaMedica Therapeutics and Edgewise Therapeutics

The main advantage of trading using opposite DiaMedica Therapeutics and Edgewise Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Edgewise Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will offset losses from the drop in Edgewise Therapeutics' long position.
The idea behind DiaMedica Therapeutics and Edgewise Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data